CSV November 24, 2022 through November 24, 2024 All Errata for USP–NF How to use

×

How to Use

- **Searching:** Type keyword in search field at top of page. Search by all or part of a monograph title. For searches using multiple criteria, you will find items that match each of the specified criteria unless quotation marks are used.
    - For example, a search on Aminosalicylic Acid Tablets will result in anything that contains “Aminosalicyclic” OR “Acid” OR “Tablets”
    - A search for “Aminosalicylic Acid Tablets” will result in anything that specifically contains “Aminosalicylic Acid Tablets”
- **Sorting:** Click on any column header title to sort alphabetically or chronologically in ascending or descending order. Note: the page load column is sorted alphabetically so that a number is ordered by first digit vs. by the actual number; thus, numbers will not always be in order.
    - For example, page 2178 will come before page 74 on a page sort.
- **Downloading:** You can download the Errata table in Comma-separated Value (.csv). The download will include the Errata that you have filtered on.
- **Importing:**You will need to import the file into Excel or Open Office with UTF-8 encoding, as opposed to simply opening it. To import, open Excel or Open Office and select import from the File drop-down. Depending on the version you are using, you should be presented with import formatting options to include UTF-8 as one of the first steps. Importing via UTF-8 should eliminate odd character conversions.

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
NATEGLINIDE	CHEMICAL	*USP43–NF38*	Online	30-Oct-2020	1-Nov-2020	*NA*	*NA*	This erratum

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
	INFORMATION							applies to the USP-NF ONLINE platform only. See http://uspnf.com/nateglinide-err-img-20201030 for correction
OIL-SOLUBLE VITAMINS WITH MINERALS TABLETS	CONTAMINANTS	*USP43–NF38*	5378	30-Oct-2020	1-Nov-2020	*NA*	*NA*	Change *Absence of Specified Microorganisms <2022>, Test Procedures, Test for Absence of Salmonella Species* and *Absence of Specified Microorganisms <2022>, Test Procedures, Test for Absence of Salmonella Species*: to: *Absence of Specified*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
LOSS ON IGNITION	INTRODUCTION	*USP43–NF38*	Online	30-Oct-2020	1-Nov-2020	*NA*	*NA*	*Microorganisms <2022>, Test Procedures, Test for Absence of Salmonella Species* and *Test for Absence of Escherichia coli:* In paragraph 3: Change Upon completion of each ignition, cover the crucible, and allow it to cool in a desiccator to room temperature before weighing. to: Upon completion of each ignition, cover the crucible, and allow it to cool in a desiccator

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								to room temperature before weighing accurately.
OXYGEN	IMPURITIES	*USP43–NF38*	3347	30-Oct-2020	1-Nov-2020	*NA*	*NA*	Change *Impurities Testing in Medical Gases Assay* ?413? to: *Impurities Testing in Medical Gases* ?413?
LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE TABLETS	ASSAY/ *Procedure*	*First Supplement to USP43–NF38*	Online	30-Oct-2020	1-Nov-2020	*NA*	*NA*	In *Buffer A*: Change monobasic potassium phosphate to: monobasic sodium phosphate
PRAZIQUANTEL TABLETS	PERFORMANCE TESTS/ *Dissolution <711>*	*USP43–NF38*	3650	30-Oct-2020	1-Nov-2020	*NA*	*NA*	In *For products for veterinary use/Apparatus 2*: Change peak vessels to: apex vessels
CELL-BASED	ANALYTICAL	*USP43–NF38*	7400	30-Oct-2020	1-Nov-2020	*NA*	*NA*	In *In-Process*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
ADVANCED THERAPIES AND TISSUE-BASED PRODUCTS	METHODS							*Control s*/paragraph 2: Change Refer to *Risk Assessment* for discussion on critical process parameters (CPP). to: Refer to *Quality Systems* for discussion on critical process parameters (CPP). AND In *Final Product Release Specifi cations/Dose-Defining Assays* /paragraph 3: Change relay to: rely
VOLUMETRIC APPARATUS	STANDARDS OF ACCURACY	*First Supplement to USP43–NF38*	Online	30-Oct-2020	1-Nov-2020	*NA*	*NA*	In paragraph 3: Change and then touched against

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								the wall of the receiving vessel to drain the tips. to: and then touched against the wall of the receiving vessel to drain the pipet tip.
OXYGEN 93 PERCENT	IMPURITIES	*USP43–NF38*	3347	30-Oct-2020	1-Nov-2020	*NA*	*NA*	Change *Impurities Testing in Medical Gases Assay* ?413? to: *Impurities Testing in Medical Gases* ?413?
GALANTAMINE EXTENDED-RELEASE CAPSULES	ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>*	*First Supplement to USP43–NF38*	Online	30-Oct-2020	1-Nov-2020	*NA*	*NA*	In USP Galantamine Hydrobromide Related Compounds Mixture RS: Change Anhydrogalantamine; (4a*S*,8a*S*)-3-Methoxy-11-

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								methyl-9,10,11,12-tetrahydro-4a*H*-benzo[2,3]benzofuro[4,3-*cd*]azepine. $C_{17}H_{19}NO_2$ to: Anhydrogalantamine; (4a*S*,8a*S*)-3-Methoxy-11-methyl-9,10,11,12-tetrahydro-4a*H*-benzo[2,3]benzofuro[4,3-*cd*]azepine. $C_{17}H_{19}NO_2$ 269.34
GALANTAMINE TABLETS	PERFORMANCE TESTS/ *Dissolution <711>*	*USP43–NF38*	2081	30-Oct-2020	1-Nov-2020	*NA*	*NA*	In *Test 3*/*Apparatus 2*: Change peak vessels to: apex vessels
DACTINOMYCIN	IDENTIFICATION/*A.*	*USP43–NF38*	1227	25-Sep-2020	1-Oct-2020	*NA*	*NA*	Change *Spectroscopic Identification Tests* ?197?, *Ultraviolet*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Spectroscopy: 197U to: *Spectroscopic Identification Tests* ?197?, *Ultraviolet-Visible Spectroscopy*: 197U
TELMISARTAN TABLETS	IDENTIFICATION/*A.*	*USP43–NF38*	4240	25-Sep-2020	1-Oct-2020	*NA*	*NA*	Change *Spectroscopic Identification Tests* ?197?, *Ultraviolet Spectroscopy*: 197U: to: *Spectroscopic Identification Tests* ?197?, *Ultraviolet-Visible Spectroscopy*: 197U:
NICOTINE TRANSDERMAL SYSTEM	PERFORMANCE TESTS/*Drug Release* <724>	*USP43–NF38*	3153	25-Sep-2020	1-Oct-2020	*NA*	*NA*	In *Tests 1, 2, 4*, and *5*/ *Tolerances*: Change conform to *Dissolution*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								<711>, *Acceptance Table 1*. to: conform to *Acceptance Table 1*.
CEFTIOFUR HYDROCHLORIDE	IMPURITIES/*High Molecular Weight Impurities*	*USP43–NF38*	875	25-Sep-2020	1-Oct-2020	*NA*	*NA*	In *Mobile phase*: Change 10 g/L of electrophoresis grade sodium dodecyl sulfate in *Solution A*. to: 10 g/L of electrophoresis grade sodium dodecyl sulfate in *Solution B*.
DESVENLAFAXINE SUCCINATE	IDENTIFICATION/*A.*	*USP43–NF38*	1283	25-Sep-2020	1-Oct-2020	*NA*	*NA*	Change *Infrared Absorption* ?197?: [Note—Methods described in ?197K? or ?197A? may be used.] to: *Spectroscopic*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Identification Tests ?197?, *Infrared Spectroscopy*: 197K or 197A
DESVENLAFAXINE FUMARATE	IDENTIFICATION/*A.*	*USP43–NF38*	1281	25-Sep-2020	1-Oct-2020	*NA*	*NA*	Change *Infrared Absorption* ?197?: [Note—Methods described in ?197K? or ?197A? may be used.] to: *Spectroscopic Identification Tests* ?197?, *Infrared Spectroscopy*: 197K or 197A
METAXALONE TABLETS	IMPURITIES	*Revision Bulletin (Official September 01, 2020)*	Online	25-Sep-2020	1-Oct-2020	*NA*	*NA*	Change *Organic Impurities* to: IMPURITIES *Organic Impurities*
DALFAMPRIDINE	IDENTIFICATION/*A*.	*USP43–NF38*	1228	25-Sep-2020	1-Oct-2020	*NA*	*NA*	Change *Infrared Absorption*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								?197?: [Note—Methods described in ?197K? or ?197A? may be used.] to: *Spectroscopic Identification Tests* ?197?, *Infrared Spectroscopy*: 197K or 197A
TILETAMINE HYDROCHLORIDE	IDENTIFICATION/*B.*	*USP43–NF38*	4382	25-Sep-2020	1-Oct-2020	*NA*	*NA*	Change *Spectroscopic Identification Tests* ?197?, *Ultraviolet Spectroscopy*: 197U— to: *Spectroscopic Identification Tests* ?197?, *Ultraviolet-Visible Spectroscopy*: 197U—
AMIODARONE HYDROCHLORIDE	IDENTIFICATION/*A.*	*USP43–NF38*	Online	25-Sep-2020	1-Oct-2020	*NA*	*NA*	This erratum applies to the *USP-NF* online

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								platform only. Change *Infrared Absorption* ?197K? to: *Spectroscopic Identification Tests* ?197?, *Infrared Spectroscopy*: 197K
CLOMIPHENE CITRATE	IDENTIFICATION/*B.*	*USP43–NF38*	1088	25-Sep-2020	1-Oct-2020	*NA*	*NA*	Change *Spectroscopic Identification Tests* ?197?, *Ultraviolet Spectroscopy*: 197U to: *Spectroscopic Identification Tests* ?197?, *Ultraviolet-Visible Spectroscopy*: 197U
ETIDRONATE DISODIUM	IDENTIFICATION/*A.*	*USP43–NF38*	1782	25-Sep-2020	1-Oct-2020	*NA*	*NA*	Change *Infrared Absorption* ?197?

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								to: *Spectroscopic Identification Tests* ?197?, *Infrared Spectroscopy*
ZONISAMIDE	IDENTIFICATION/*A*.	*USP43–NF38*	4718	25-Sep-2020	1-Oct-2020	*NA*	*NA*	Change *Infrared Absorption* ?197K? to: *Spectroscopic Identification Tests* ?197?, *Infrared Spectroscopy*: 197K
DESVENLAFAXINE	IDENTIFICATION/*A*.	*USP43–NF38*	1280	25-Sep-2020	1-Oct-2020	*NA*	*NA*	Change *Infrared Absorption* ?197?: [Note—Methods described in ?197K? or ?197A? may be used.] to: *Spectroscopic Identification Tests* ?197?, *Infrared*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
VORICONAZOLE	IDENTIFICATION/*A.*	*USP43–NF38*	4643	25-Sep-2020	1-Oct-2020	*NA*	*NA*	*Spectroscopy*: 197K or 197A Change *Infrared Absorption* ?197K? to: *Spectroscopic Identification Tests* ?197?, *Infrared Spectroscopy*: 197K
AMLODIPINE BESYLATE TABLETS	IDENTIFICATION/*A.*	*USP43–NF38*	286	25-Sep-2020	1-Oct-2020	*NA*	*NA*	Change *Spectroscopic Identification Tests* ?197?, *Ultraviolet Spectroscopy*: 197U to: *Spectroscopic Identification Tests* ?197?, *Ultraviolet-Visible Spectroscopy*: 197U
CLOMIPRAMINE HYDROCHLORIDE	ADDITIONAL REQUIREMENTS/*USP*	*Revision Bulletin (Official July 08, 2020)*	Online	28-Aug-2020	1-Sep-2020	*NA*	*NA*	In USP Clomipramine Related

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
CAPSULES	*Reference Standards <11>*							Compound A RS: Change 458.89 to: 458.90
THEOPHYLLINE TABLETS	*Assay*	*USP43–NF38*	4328	28-Aug-2020	1-Sep-2020	*NA*	*NA*	Change *Mobile phase*, *Internal standard solution*, and *Standard preparation*—Prepare as directed in the *Assay* under *Theophylline*. to: *Buffer solution*—Transfer 2.72 g of sodium acetate trihydrate to a 2000-mL volumetric flask, add about 200 mL of water, and shake until dissolution is complete. Add 10.0 mL of

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								glacial acetic acid, dilute with water to volume, and mix. *Mobile phase*—Transfer 70.0 mL of acetonitrile to a 1000-mL volumetric flask, dilute with *Buffer solution* to volume, and mix. Degas, and filter before using. Make adjustments if necessary (see *System Suitability* under *Chromatography <621>*). *Internal standard solution*—Transfer about 50 mg of theobromine, accurately weighed, to a

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								100-mL volumetric flask, dissolve in 10.0 mL of 6 N ammonium hydroxide, dilute with *Mobile phase* to volume, and mix. *Standard preparation*—Dissolve an accurately weighed quantity of USP Theophylline RS in *Mobile phase*, and dilute quantitatively, and stepwise if necessary, with *Mobile phase* to obtain a solution having a known concentration of about 1 mg per mL. Transfer

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								10.0 mL of this solution to a 100-mL volumetric flask, add 20.0 mL of *Internal standard solution*, dilute with *Mobile phase* to volume, and mix to obtain a solution having a known concentration of about 0.1 mg of USP Theophylline RS per mL. AND Change *Chromatographic system* —Proceed as directed in the *Assay* under *Theophylline*. to: (see *Chromatograph*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								y <621>)—The liquid chromatograph is equipped with a 280-nm detector and a 4-mm × 30-cm column that contains packing L1. The flow rate is about 1.0 mL per minute. Chromatograph the *Standard preparation*, and record the peak responses as directed for *Procedure*: the resolution, *R*, between the theophylline and theobromine peaks is not less than 2.0, the tailing factor for the theophylline peak is not

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								more than 2.0, and the relative standard deviation for replicate injections is not more than 1.5%. AND Change *Proce dure*—Proceed as directed for *Procedure* in the *Assay* under *Theophylline*. to: *Proce dure* —Separately inject equal volumes (between 10 µL and 25 µL) of the *Standard preparation* and the *Assay preparation* into the chromatograph, and measure

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								the peak responses for the major peaks. The retention time of theophylline relative to that of theobromine is about 1.6.
SODIUM IODIDE I 123 CAPSULES	*Radiochemical purity*	*USP43–NF38*	2365	28-Aug-2020	1-Sep-2020	*NA*	*NA*	Change Homogenize 1 Capsule in 3 mL of water, add 3 mL of methanol, and centrifuge: the supernatant so obtained meets the requirements of the test for *Radiochemical purity* under *Sodium Iodide I 123 Solution*. to: Place a measured volume of a solution, containing 100 mg of

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								potassium iodide, 200 mg of potassium iodate, and 1 g of sodium bicarbonate in each 100 mL, 25 mm from one end of a 25- × 300-mm strip of chromatographic paper (*see Chromatography <621>*), and allow to dry. To the same area add a similar volume of the sample solution prepared as follows: homogenize the content from 1 Capsule in 3 mL of water and 3 mL of methanol and centrifuge. The supernatant should be

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								diluted so that it provides a count rate of about 20,000 counts per minute. Allow the spots to dry. Develop the chromatogram over a period of about 4 hours by ascending chromatography, using dilute methanol (7 in 10). Dry the chromatogram in air, and determine the radioactivity distribution by scanning with a suitable collimated radiation detector: the radioactivity of the iodide ^{123}I band is not less than 95.0% of the total

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								radioactivity, and its R_F value falls within ±5.0% of the value found for sodium iodide when determined under similar conditions. Confirmation of the identity of the iodide band is made by the addition to the suspected iodide band of 6 drops of acidified hydrogen peroxide solution (prepared by adding 6 drops of 1 N hydrochloric acid to 10 mL of hydrogen peroxide solution) followed by the

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								dropwise addition of starch TS: the development of a blue color indicates the presence of iodide.
SODIUM IODIDE I 123 CAPSULES	*Radionuclide identification*	*USP43–NF38*	2365	28-Aug-2020	1-Sep-2020	*NA*	*NA*	Change A solution or suspension of 1 or more Capsules in water responds to the test for *Radionuclide identification* under *Sodium Iodide I 123 Solution*. to: (see *Radioactivity* <821>) The gamma-ray spectrum of a solution or suspension of 1 or more Capsules in water is

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								identical to that of a specimen of ^{123}I of known purity that exhibits a major photoelectric peak having an energy of 0.159 MeV.
CARTEOLOL HYDROCHLORIDE OPHTHALMIC SOLUTION	*Assay*	*USP43–NF38*	789	28-Aug-2020	1-Sep-2020	*NA*	*NA*	Change *pH 6.0 buffer*, *Mobile phase*, *Diluent*, *Standard preparation*, *Resolution solution*, and *Chromatographic system* —Proceed as directed in the *Assay* under *Carteolol Hydrochloride*. to: *Buffer*, *Mobile phase*, *Standard stock solution*, *Standard*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								solution, *System suitability stock solution*, *System suitability solution*, *Chromatographic system*, and *System suitability*—Proceed as directed in the *Assay* under *Carteolol Hydrochloride*. AND Add *Diluent*—Prepare a mixture of *Buffer* and methanol (1:1). AND In all instances in *Procedure*: Change *Standard preparation* to: *Standard solution*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
SODIUM IODIDE I 123 CAPSULES	*Other requirements*	*USP43–NF38*	2365	28-Aug-2020	1-Sep-2020	*NA*	*NA*	Change *Other requirements* A solution or suspension prepared by homogenizing 1 or more Capsules in water to yield a concentration of not less than 1 MBq (25 µCi) per mL meets the requirements of the *Assay for radioactivity* under *Sodium Iodide I 123 Solution*. to: *Assay for radioactivity* Prepare a solution or suspension by homogenizing 1 or more Capsules in water to yield a

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								concentration of not less than 1 MBq (25 µCi) per mL. Determine the radioactivity of the resulting solution using a suitable counting assembly, by use of a calibrated system as directed under *Radioactivity <821>*.
SODIUM IODIDE I 123 CAPSULES	*Radionuclidic purity*	*USP43–NF38*	2365	28-Aug-2020	1-Sep-2020	*NA*	*NA*	Change A solution or suspension of 1 or more Capsules in water responds to the test for *Radionuclidic purity* under *Sodium Iodide I 123 Solution*. to: (see *Radioactivity*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								<821>) Using a suitable counting assembly, determine the radionuclidic purity of a solution or suspension of 1 or more Capsules in water: not less than 90% of the total radioactivity is present as I 123.
VITAMIN D ASSAY	ASSAY/ *Chromatographic Methods*	*USP43–NF38*	6808	28-Aug-2020	1-Sep-2020	*NA*	*NA*	In the second Calculate statement in *Procedure 7/ Analysis/ Precholecalciferol and pre-ergocalciferol response factor*: Change pre-ergolecalciferol

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
FUROSEMIDE TABLETS	*Limit of furosemide related compound B*	*USP43–NF38*	2056	31-Jul-2020	1-Aug-2020	*NA*	*NA*	to: pre-ergocalciferol Change *Mobile phase*, *Diluting solution*, *System suitability solution*, and *Chromatographic system*—Prepare as directed in the test for *Related compounds* under *Furosemide*. to: *Mobile phase*—Prepare a filtered and degassed mixture of water, tetrahydrofuran, and glacial acetic acid (70:30:1). Make adjustments if

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								necessary (see *System Suitability* under *Chromatography* <621>). *Diluting solution*—Dilute 22 mL of glacial acetic acid with a mixture of acetonitrile and water (50:50) to 1000 mL, and mix. *System suitability solution*—Dissolve suitable quantities of USP Furosemide RS and USP Furosemide Related Compound A RS in *Diluting solution* to obtain a solution containing

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								about 20 µg per mL and 12 µg per mL, respectively. *Chromatographic system* (see *Chromatography* <621>)—The liquid chromatograph is equipped with a detector capable of recording at both 254 nm and 272 nm and a 4.6-mm x 25-cm column that contains packing L1. [NOTE—The 2,4-dichloro-5-sulfamoylbenzoic acid impurity does not respond at 272 nm and the 2,4-bis(furfurylamino)-5-sulfamoylbenzoic acid impurity has a

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								very intense absorbance at 254 nm.] The flow rate is about 1.0 mL per minute. Chromatograph the *System suitability solution*, and record the peak responses as directed for *Procedure*: the resolution, *R*, between furosemide and furosemide related compound A is not less than 2.5; and the relative standard deviation determined from furosemide is not more than 2.0%. [NOTE—The response for

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								furosemide is at 254 nm.]
NUCLEIC ACID-BASED TECHNIQUES—GENERAL	*Appendix 1*	*USP43–NF38*	7865	31-Jul-2020	1-Aug-2020	*NA*	*NA*	In footnote 1: Change http://ts.nist.gov/measurementservices/referencematerials/index.cfm. to: https://www.nist.gov/srm.
METOPROLOL SUCCINATE EXTENDED-RELEASE TABLETS	ADDITIONAL REQUIREMENTS	*USP43–NF38*	2918	31-Jul-2020	1-Aug-2020	*NA*	*NA*	In *Labeling*: Change as metoprolol succinate $[(C_{15}H_{25}NO_3)_2 \cdot C_4H_6O_6]$. to: as metoprolol tartrate $[(C_{15}H_{25}NO_3)_2 \cdot C_4H_6O_6]$.
FUROSEMIDE INJECTION	*Assay*	*USP43–NF38*	2054	31-Jul-2020	1-Aug-2020	*NA*	*NA*	Change *Mobile phase*, *Diluting solution*, *System suitability solution*, and *Chromatographi*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								c *system*—Prepare as directed in the test for *Related compounds* under *Furosemide*. to: *Mobile phase*—Prepare a filtered and degassed mixture of water, tetrahydrofuran, and glacial acetic acid (70:30:1). Make adjustments if necessary (see *System Suitability* under *Chromatography* <621>). *Diluting solution*—Dilute 22 mL of glacial acetic acid with a mixture of acetonitrile and

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								water (50:50) to 1000 mL, and mix. *System suitability solution* —Dissolve suitable quantities of USP Furosemide RS and USP Furosemide Related Compound A RS in *Diluting solution* to obtain a solution containing about 20 µg per mL and 12 µg per mL, respectively. *Chromatographic system* (see *Chromatography* <621>)—The liquid chromatograph is equipped with

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								a detector capable of recording at both 254 nm and 272 nm and a 4.6-mm x 25-cm column that contains packing L1. [NOTE—The 2,4-dichloro-5-sulfamoylbenzoic acid impurity does not respond at 272 nm and the 2,4-bis(furfurylamino)-5-sulfamoylbenzoic acid impurity has a very intense absorbance at 254 nm.] The flow rate is about 1.0 mL per minute. Chromatograph the *System suitability solution*, and record the peak

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								responses as directed for *Procedure*: the resolution, *R*, between furosemide and furosemide related compound A is not less than 2.5; and the relative standard deviation determined from furosemide is not more than 2.0%. [NOTE—The response for furosemide is at 254 nm.]
METHYLDOPA IDENTIFICATIO TE HYDROCHL N ORIDE	*USP43–NF38*	2880		31-Jul-2020	1-Aug-2020	*NA*	*NA*	In *C*: Change It responds to *Identification* test *C* under Methyldopa. to: *Sample*: 10 mg *Analysis*: To the *Sample* add

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
FUROSEMIDE TABLETS	*Assay*	*USP43–NF38*	2056	31-Jul-2020	1-Aug-2020	*NA*	*NA*	0.15 mL of a solution of ninhydrin in sulfuric acid (1 in 250): a dark purple color is produced within 5–10 min. Add 0.15 mL of water. *Acceptance criteria*: The color changes to pale brownish yellow. Change: *Mobile phase*, *Diluting solution*, *System suitability solution*, and *Chromatographic system*—Prepare as directed in the test for *Related compounds* under

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Furosemide. to: *Mobile phase*—Prepare a filtered and degassed mixture of water, tetrahydrofuran, and glacial acetic acid (70:30:1). Make adjustments if necessary (see *System Suitability* under *Chromatography* <621>). *Diluting solution*—Dilute 22 mL of glacial acetic acid with a mixture of acetonitrile and water (50:50) to 1000 mL, and mix. *System suitability solution* —Dissolve

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								suitable quantities of USP Furosemide RS and USP Furosemide Related Compound A RS in *Diluting solution* to obtain a solution containing about 20 µg per mL and 12 µg per mL, respectively. *Chromatographic system* (see *Chromatography* <621>)—The liquid chromatograph is equipped with a detector capable of recording at both 254 nm and 272 nm and a 4.6-mm x 25-cm column

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								that contains packing L1. [NOTE—The 2,4-dichloro-5-sulfamoylbenzoic acid impurity does not respond at 272 nm and the 2,4-bis(furfurylamino)-5-sulfamoylbenzoic acid impurity has a very intense absorbance at 254 nm.] The flow rate is about 1.0 mL per minute. Chromatograph the *System suitability solution*, and record the peak responses as directed for *Procedure*: the resolution, *R*, between furosemide and furosemide

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								related compound A is not less than 2.5; and the relative standard deviation determined from furosemide is not more than 2.0%. [NOTE—The response for furosemide is at 254 nm.]
DIBASIC CALCIUM PHOSPHATE DIHYDRATE	IMPURITIES	*USP43–NF38*	708	31-Jul-2020	1-Aug-2020	*NA*	*NA*	In *Chloride and Sulfate, Chloride* <221>: Change *Sample*: 0.2 g of of Dibasic Calcium Phosphate Dihydrate to: *Sample*: 0.2 g of Dibasic Calcium Phosphate Dihydrate
SOTALOL HYD	*Identification*	*USP43–NF38*	4105	31-Jul-2020	1-Aug-2020	*NA*	*NA*	Change

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
ROCHLORIDE TABLETS								Weigh and powder a quantity of the Tablets, equivalent to about 250 mg of sotalol hydrochloride, and transfer to a 50-mL volumetric flask. Add 25 mL of methanol, and shake for 10 minutes. Dilute with methanol to volume, mix, and filter: the filtrate so obtained meets the requirements for *Identification* test B under *Sotalol Hydrochloride*. to: *Thin-Layer Chromatographic Identification Test* <201>—

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Test solution—Weigh and powder a quantity of the Tablets, equivalent to about 250 mg of sotalol hydrochloride, and transfer to a 50-mL volumetric flask. Add 25 mL of methanol, and shake for 10 minutes. Dilute with methanol to volume, mix, and filter. Use the filtrate. *Developing solvent system*: a mixture of chloroform and methanol (70:30). *Proce dure*—Proceed as directed in the chapter, except to place

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								two 25-mL beakers, each containing about 10 mL of ammonium hydroxide, on the bottom of the chromatographic chamber that is lined with filter paper and contains the *Developing solvent system*, allow to equilibrate for 15 minutes, then place the plate in the chamber, and develop the chromatograms until the solvent front has moved about two-thirds of the length of the plate: meets the requirements.
ANTI-FACTOR XA AND ANTI-	*Anti-Factor Xa and Anti-Factor*	*USP43–NF38*	6611	31-Jul-2020	1-Aug-2020	*NA*	*NA*	Change *Anti-Factor Xa*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
FACTOR IIA ASSAYS FOR UNFRACTIONATED AND LOW MOLECULAR WEIGHT HEPARINS	*IIa Assays for Low Molecular Weight Heparins*							*Activity for Low Molecular Weight Heparin* to: The following procedure is used where specified in the individual monographs. This assay can be performed manually in plastic tubes utilizing heated block stations or water bath. Microtiter plate equipment with a reader and automated coagulometer can improve reproducibility and throughput. Acetic acid solution (stopping solution) is used for manual and microtiter plate

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								assay. Automated coagulometers measure initial kinetic rate, and because of that, stopping of the reaction is not needed. *Anti-Factor Xa Activity for Low Molecular Weight Heparin*
DESIGN AND ANALYSIS OF BIOLOGICAL ASSAYS	COMBINATION OF INDEPENDENT ASSAYS/*Method 2*	*USP43–NF38*	6543	31-Jul-2020	1-Aug-2020	*NA*	*NA*	In the second bullet in *Alternate weights* for inter-assay component of variation: Delete the duplicate equation
MINOCYCLINE HYDROCHLORIDE EXTENDED-RELEASE TABLETS	PERFORMANCE TESTS/ *Dissolution <711>*	*Revision Bulletin (Official September 01, 2019)*	Online	31-Jul-2020	1-Aug-2020	*NA*	*NA*	In *Test 4*/*Table 5*: Change 45/Tablet and 90 mg/Tablet to: 45 mg/Tablet and 90 mg/Tablet
FUROSEMIDE	*Limit of*	*USP43–NF38*	2054	31-Jul-2020	1-Aug-2020	*NA*	*NA*	Change

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
INJECTION	*furosemide related compound B*							*Mobile phase*, *Diluting solution*, *System suitability solution* and *Chromatographic system*—Prepare as directed in the test for *Related compounds* under *Furosemide*. to: *Mobile phase*—Prepare a filtered and degassed mixture of water, tetrahydrofuran, and glacial acetic acid (70:30:1). Make adjustments if necessary (see *System Suitability* under *Chromatograph*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								y <621>). *Diluting solution*—Dilute 22 mL of glacial acetic acid with a mixture of acetonitrile and water (50:50) to 1000 mL, and mix. *System suitability solution*—Dissolve suitable quantities of USP Furosemide RS and USP Furosemide Related Compound A RS in *Diluting solution* to obtain a solution containing about 20 µg per mL and 12 µg per mL, respectively.

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Chromatographic system (see *Chromatography* <621>)—The liquid chromatograph is equipped with a detector capable of recording at both 254 nm and 272 nm and a 4.6-mm x 25-cm column that contains packing L1. [NOTE—The 2,4-dichloro-5-sulfamoylbenzoic acid impurity does not respond at 272 nm and the 2,4-bis(furfurylamino)-5-sulfamoylbenzoic acid impurity has a very intense absorbance at 254 nm.] The flow rate is

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								about 1.0 mL per minute. Chromatograph the *System suitability solution*, and record the peak responses as directed for *Procedure*: the resolution, *R*, between furosemide and furosemide related compound A is not less than 2.5; and the relative standard deviation determined from furosemide is not more than 2.0%. [NOTE—The response for furosemide is at 254 nm.]
ETHAMBUTOL HYDROCHLOR	IM PURITIES/*Limit*	*USP43–NF38*	1762	31-Jul-2020	1-Aug-2020	*NA*	*NA*	In *Acceptance criteria*: Change

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
IDE	*of Aminobutanol*							The fluorescence intensity of the solution from the *Sample solution* is NMT 1.0% of the difference between the intensities of the two solutions. to: The fluorescence intensity of the solution from the *Sample solution* is NMT the difference between the intensities of the two solutions (NMT 1.0%).
ATORVASTATIN CALCIUM	ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>*	*USP43–NF38*	414	26-Jun-2020	1-Jul-2020	*NA*	*NA*	In USP Atorvastatin Related Compound B RS: Change 3*S*,5*R* Isomer, or

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								(3*S*,5*R*)-7-[3-(phenylcarbamoyl)-5-(4-fluorophenyl)-2-isopropyl-4-phenyl-1*H*-pyrrol-1-yl]-3,5-dihydroxyheptanoic acid, calcium salt. to: Calcium (3*S*,5*R*)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-(phenylcarbamoyl)-1*H*-pyrrol-1-yl]-3,5-dihydroxyheptanoate (1:2); also known as 3*S*,5*R* Isomer, or (3*S*,5*R*)-7-[3-(phenylcarbamoyl)-5-(4-fluorophenyl)-2-isopropyl-4-phenyl-1*H*-pyrrol-1-yl]-3,5-

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								dihydroxyhepta noic acid, calcium salt.
DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE TABLETS	*Assay*	*USP43–NF38*	1439	26-Jun-2020	1-Jul-2020	*NA*	*NA*	In *Procedure*: Change 694.83/676.83)(250)$C_A(r_U/r_S)$ in which 694.83 and 676.83 are the molecular weights of atropine sulfate monohydrate and anhydrous atropine sulfate, respectively; to: (694.84/676.82)(250)$C_A(r_U/r_S)$ in which 694.84 and 676.82 are the molecular weights of atropine sulfate monohydrate and anhydrous atropine sulfate, respectively;

Pagination

- First page « First
- Previous page ‹ Previous
- Page 1
- Page 2
- Page 3
- Page 4
- Page 5
- Page 6
- Page 7
- Page 8
- Page 9
- …
- Next page Next ›
- Last page Last »